ArticleMaterials today. Bio2026
Extracellular matrix-mimetic ink for 3D printing and minimally invasive delivery of shape-memory constructs.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging Scales: Integrating Hyaluronan-Based Nanoencapsulation into 3D Hydrogel Constructs for Advanced Therapeutics-A Comprehensive Review.Gels (Basel, Switzerland) · 2026Review
- Three-Dimensional Bioprinting and Rose-Inspired Medical Applications.Biomimetics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct injection of hydrogels loaded with therapeutics holds great promise for tissue regeneration; however, injectable hydrogels typically fill defect spaces without spatiotemporal control, which is critical for regenerating certain tissues. Conversely, 3D printing enables the fabrication of patterned hydrogel constructs but often requires invasive surgical implantation. Here, we present a novel strategy for the non-invasive delivery of 3D-printed constructs. Specifically, we developed gallic acid-modified hyaluronic acid (HA) that was crosslinked for the first time using potassium iodide (KI) as a catalyst, without the need for an initiator or light exposure. This also enabled protein conjugation with gelatin and collagen to obtain an extracellular matrix (ECM)-mimetic ink for 3D printing. We determined the distinct pKa values of the phenolic hydroxy groups of gallol-modified HA, which were utilized to achieve 3D printing at acidic pH, followed by efficient solution-free covalent crosslinking using ammonia gas to ensure complete crosslinking. This approach enabled efficient printing through fine nozzles (G32) and produced robust structures. The printed scaffolds were subsequently loaded into a larger needle and injected, demonstrating shape-memory properties by retaining their geometry post-injection. Furthermore, the scaffolds supported stem cell coating, where the stemness and differentiation of stem cells could be modulated by hydrogel composition and culture conditions, including chondrogenic differentiation towards cartilage-like constructs using TGF-β3. This strategy offers a versatile platform for developing HA-based hydrogels capable of protein conjugation, 3D printing, cell or biomolecule coating, and minimally invasive implantation while maintaining structural fidelity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.